Circio Holding ASA: Minutes from the extraordinary general meeting 25 August 2026
* Dr. Dinah Sah and Dr. Robert Burns were elected as new Directors of the
Board
* Dr. Sah is an RNA and gene therapy industry veteran with prior experience as CSO of Voyager Therapeutics and VP of Research of Alnylam Pharmaceuticals
* Dr. Burns has served on the Board and R&D committee of Circio for over 15
years
* All other items on the EGM agenda were passed
Oslo, 25 August 2026: Circio Holding ASA (the "Company") held an extraordinary general meeting today. The meeting was held as a physical meeting at the Company's offices at Tordenskiolds gate 2, 0160 Oslo, Norway.
All resolutions were made in accordance with the proposals from the board of directors and the nomination committee, including the election of new members to the board of directors, decision on the use of electronic communication towards shareholders, and the board was granted a renewed authorization to increase the share capital.
The minutes from the extraordinary general meeting are attached hereto and will also be made available on the Company's website
circio.com/investors/general-meetings
"Circio has now entered its next phase of development, aiming to bring a lead therapeutic candidate forward to clinical entry in 2029. To ensure Circio continues to make well-founded pre-clinical development decisions, we have further strengthened the Board with deep translational expertise in the RNA and gene therapy fields," said Damian Marron, Chairman of Circio. "We are therefore very pleased to announce Dr. Sah as a new Board Director. She brings precisely the experience we need at this stage, having navigated several RNA and AAV gene therapy programs from early scientific promise into the clinic and through early clinical development. That Circio is able to attract a new Board Director of Dr. Sah s caliber is a strong testament to the robustness and promise of our circVec technology platform, as well as the quality of our current R&D leadership. The re-nomination of Dr. Robert Burns ensures we retain his in-depth knowledge of our technology and his established contributions to supporting Circio's management with the highest standards and to continuing strong Corporate Governance."
"Circio s innovative circular RNA expression technology shows real promise for solving some of the major challenges of current AAV gene therapies," said Dr.
Dinah Sah, new Director of the Board of Circio. "The circVec platform has significant potential to enable much lower doses of AAV gene therapy;
retaining similar pharmacology in target tissues, while reducing off-target expression and cellular stress responses. These are very important translational advantages for next generation gene therapy. The versatile circVec technology may also have applications for other drug classes and represents a highly interesting platform that I very much look forward to being part of advancing."
------------------------------------------------------------------------------
Biography -- Dr. Dinah Sah
Dr. Dinah Sah is an executive in the biotechnology industry with more than 30 years of R&D experience building and leading high performance start-up companies and teams from inception to rapidly advance novel, transformative technologies for drug discovery and development, in multiple therapeutic areas and with new classes of drugs. Her primary expertise is AAV gene therapy and RNAi therapeutics for neurological disorders, especially neurodegenerative diseases. She currently serves on multiple scientific advisory boards and boards of biotechnology, venture capital and non-profit organizations. Dr. Sah was a founding member and Chief Scientific Officer of Voyager Therapeutics, focused on the discovery and development of AAV gene therapies for the treatment of severe neurodegenerative diseases. Prior to Voyager, she was Vice President of Research at Alnylam Pharmaceuticals which pioneered siRNA therapeutics as a new class of drugs and also served at Biogen and Signal Pharmaceuticals. Dr. Sah's work led to the discovery of novel drug targets and drug candidates that advanced into clinical development. Her leadership of multiple programs from early research through Phase 1 clinical trials included notably the transthyretin (TTR) siRNA therapeutic program (patisiran) which provided the first, landmark demonstration of human proof-of-mechanism for this novel class of drugs, in TTR amyloidosis -- peripheral neuropathy patients. This work ultimately led to FDA approval of the first systemic RNAi therapy, ONPATTRO® (patisiran), which has transformed the lives of these patients and paved the way for multiple subsequent RNAi therapeutics.
Dr. Sah is an inventor on more than 40 patents. Her publications across diverse research areas include articles in journals such as Nature Medicine, Nature Biotechnology, Nature Neuroscience, Molecular Therapeutics, Neuron, PNAS and the New England Journal of Medicine. Dr. Sah received her B.S. in Biology from the Massachusetts Institute of Technology and her Ph.D. in Neurobiology from Harvard University.
Biography -- Dr. Robert Burns
Dr. Burns has been active in the life science/biotechnology sphere since the mid-1970s initially in the diagnostics segment of the industry and from 1989 in therapeutics R&D. He has served as CEO of Oslo based Affitech (NASDAQ), New Jersey based Celldex (NASDAQ), and Basel based 4-Antibody, each of these companies developing antibody based therapeutic products and each company needing to be reshaped for success. Two antibody-based checkpoint inhibitor products generated during his time at 4-Antibody are now in Phase 3 trials for colorectal cancer. Prior to those roles, he served in academia in a business development and licensing role at Ludwig Cancer Research (LCR) in New York during the period in which LCR and others were leading the field of clinical research on checkpoint inhibition in cancer therapy. Previously, he operated in business & commercial development roles in OGS plc (UK), British Biotechnology plc (UK), and Applied bioTechnology (US). He has also served on several biotechnology company boards: Piramed (UK), as Chairman of Haemostatix (UK), and Affibody (Sweden) where he currently serves as chairman. He also currently advises Oxford based iuvantium (immunomodulatory inorganic layered double hydroxides).
He received his PhD in chemistry from Birmingham University (UK) in 1971 and subsequently served as a scientific and technical advisor in the then UK Ministry of Health before joining Corning Medical (a division of Corning Inc) serving in a variety of business development, marketing, and manufacturing roles in both the UK and USA.
This information is subject to disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.
For further information, please contact:
Erik Digman Wiklund, CEO Phone: +47 413 33 536
Email: erik.wiklund@circio.com
Lubor Gaal, CFO Phone: +34 683 34 3811
Email: lubor.gaal@circio.com
About Circio
Building circular RNA expression systems for enhanced gene and cell therapies
Circio Holding ASA is a biotechnology company developing novel circular RNA expression technology for gene and cell therapy.
Circio has established a unique circular RNA (circRNA) vector expression technology for next generation RNA, DNA and viral therapeutics. The proprietary circVec platform is based on a modular genetic construct designed for efficient biogenesis of multifunctional circRNA inside target cells. The circVec platform has applications in multiple therapeutic settings, including genetic medicine, cell therapy and chronic disease. It has demonstrated 75-fold increased RNA half-life and up to 50-fold enhanced protein expression vs. conventional mRNA-based viral and non-viral vector systems, with the potential to become a new gold-standard gene expression technology. The circVec R&D activities are being conducted by the wholly owned subsidiary Circio AB in Stockholm, Sweden.